Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evolved to
become the centerpiece of therapy for myelofibrosis (MF), and its use in patients with …

There has been a major revolution in the management of patients with myeloproliferative
neoplasms (MPN), and in particular those with myelofibrosis and extensive splenomegaly …

Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative
neoplasms with variable risk of evolution into post-PV and post-ET myelofibrosis, from now …

Background Myelofibrosis is a chronic myeloproliferative neoplasm characterised by
splenomegaly, cytopenias, bone marrow fibrosis, and debilitating symptoms including …

Momelotinib, a small-molecule inhibitor of Janus kinase 1 and Janus kinase 2, has
demonstrated efficacy in myelofibrosis patients with 300 mg, once-daily dosing. This open …

Abstract Combined Janus kinase 1 (JAK1) and JAK2 inhibition therapy effectively reduces
splenomegaly and symptom burden related to myelofibrosis but is associated with dose …

Transporters govern the access of molecules to cells or their exit from cells, thereby
controlling the overall distribution of drugs to their intracellular site of action. Clinically …

Background Next-generation sequencing (NGS) of cancer gene panels are widely applied
to enable personalized cancer therapy and to identify novel oncogenic mutations. Methods …

NS-018 is a Janus-activated kinase 2 (JAK2)-selective inhibitor, targeting the JAK–signal
transducer and activator of transcription (STAT) pathway that is deregulated in myelofibrosis …

Myeloproliferative neoplasms (MPN) are a group of disorders defined by clonal proliferation
of mature myeloid cells with overlapping clinical features. The driver mutations of these …